(Reuters) – The U.S. government has entered an agreement with life sciences company Cytiva, a unit of Danaher Corp, to expand the manufacturing of products needed to make COVID-19 vaccines, the U.S. Department of Health and Human Services (HHS) said on Tuesday.
Under the deal, Cytiva will receive about $31 million to scale up manufacturing of vaccine-related products, including cell cultures and hardware such as bioreactors used for the culturing of cells and antibodies.
The grant will help the company ramp up the manufacturing capabilities of its Massachusetts and Utah facilities.
The U.S. government has till date agreed to pay more than $1.1 billion to purchase needles, syringes, vials and supply kits, as well as expand manufacturing capacity for COVID-19 vaccines and therapeutics in the United States, the
The first presidential debate was less an argument over policies and ideas than a boxing match. But there was at least one brief exchange that bordered on an ideological debate.
“We prefer a vaccine,” said Democratic presidential nominee Joe BidenJoe BidenFederal judge shoots down Texas proclamation allowing one ballot drop-off location per county Sanders endorses more than 150 down-ballot Democrats Debate commission cancels Oct. 15 Trump-Biden debate MORE about the COVID-19 pandemic. “But I don’t trust [President TrumpDonald John TrumpFederal judge shoots down Texas proclamation allowing one ballot drop-off location per county Nine people who attended Trump rally in Minnesota contracted coronavirus Schiff: If Trump wanted more infections ‘would he be doing anything different?’ MORE] at all, and neither do you. I know you don’t. What we trust is a scientist.”
“You don’t trust Johnson & Johnson, Pfizer?” the president responded.
Unfortunately, the discussion then drifted
Data Source: Bloomberg
3D Note: As part of our ongoing commentary concerning the coronavirus global contagion and its impact on human and global markets, we remind readers that the situation remains fluid as evidenced by volatile market reactions to most new developments, although the pace of these reactions seems to have slowed down from March/April. In addition to our bi-monthly articles and periodic podcasts, 3D has started publishing mid-month updates to our advisor partners as we navigate through the coronavirus pandemic. Please contact us if you would like to be added to the distribution list.
Market action during the third quarter was largely uneventful despite a moderate pickup in volatility and a “pause” in the global reflation trade. The first two months saw rallies in the global reflation trade, broadly represented by growth technology stocks, emerging markets, commodities/non-U.S. currencies, and corporate credit, only to see investors back
Moncef Slaoui, head of the White House’s “Operation Warp Speed” project to develop a coronavirus vaccine, listens to U.S. President Donald Trump deliversremarks about vaccine development in the Rose Garden of the White House on May 15, 2020 in Washington, DC. Credit – Drew Angerer—Getty Images
As the COVID-19 pandemic enters its 10th month, the pressure to develop an effective vaccine, or vaccines, continues to mount. Speaking at the Johns Hopkins University and University of Washington Vaccine Symposium online, Dr. Moncef Slaoui, scientific head of Operation Warp Speed—the government organization funding and supporting development and distribution of COVID-19 vaccines—provided the latest updates on when a vaccine (and how many doses) might be available in coming months.
Perhaps most strikingly, Slaoui said that the government has told vaccine manufacturers not to seek authorization of their drugs from the Food and Drug Administration (FDA) until
Vaccine expert and whistleblower Rick Bright on Tuesday resigned from the federal government, his attorneys announced in a statement. Earlier this year, Bright was removed from a top position at the Department of Health and Human Services.
Bright, a high-ranking scientist, has said the Trump administration’s response to thehas been slow and chaotic, prioritizing politics over science. Bright earlier this year filed a running over 300 pages.
Now, Bright has submitted his resignation to the National Institutes of Health effective immediately and has filed an updated complaint with the Office of Special Counsel alleging constructive discharge based on the failure of NIH leadership to assign him meaningful work, according to Bright’s lawyers.
“Dr. Bright was forced to leave his position at NIH because he can no longer sit idly by and work for an administration that ignores scientific expertise, overrules public health guidance and disrespects
A coronavirus vaccine is likely to be given to elderly people first when it arrives, a government advisor has said.
Professor Adam Finn, from the University of Bristol, who is a member of the joint committee on vaccination and immunisation (JCVI), said age should determine those given priority rather than occupation.
He told BBC Radio 4’s Today programme that evidence collected by the JCVI, which advises the government on vaccines, showed carers and those who are vulnerable should also receive the jab ahead of the rest of the population.
“People should not imagine that there’s going to be a sudden and complete solution,” he said on Tuesday.
“These early vaccines I hope will work to some extent, but there are lots of different vaccines, and they will not all work equally effectively.
(Reuters) – The United States should opt into the World Health Organization-led COVAX facility for COVID-19 vaccine distribution, an independent expert panel tapped by top U.S. health officials to advise on vaccine allocation said on Friday.
“The U.S. government should commit to a leadership role in the equitable allocation of COVID-19 vaccine globally by opting into the COVAX facility …. deploying a proportion of the U.S. vaccine supply for global allocation,” the National Academies of Sciences, Engineering and Medicine said in a statement.
The COVAX facility, led by the WHO and the public-private partnership GAVI vaccine alliance, gives access to COVID-19 vaccine candidates in development. The White House said in September it would not join the global effort, because of the WHO’s involvement.
The panel’s report said that participating in the global allocation of COVID-19 vaccines, including the possibility of devoting some of the reserved capacity of the U.S. supply,